Every material Form 8-K EXOZYMES INC. has filed with the SEC since July 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
eXoZymes Inc. filed an 8-K attaching an investor presentation dated October 6, 2026. The company says the presentation may be provided to investment bankers, offering participants, and current and potential investors in its securities. The filing contains no financial results, guidance, or transaction terms, so it gives shareholders no new financial figures.
Filing date: October 9, 2026; investor presentation dated October 6, 2026 (Exhibit 99.1)
Items reported: 8.01 Other Events and 9.01 Financial Statements and Exhibits
Presentation may be shared with investment bankers, offering participants, and current and potential investors
Exozymes said it will hold its 2026 annual shareholder meeting on November 13, 2026. The company plans to send its proxy statement and proxy to shareholders on or about September 28, 2026, with a record date of September 15, 2026. The filing is administrative and contains no financial results or other business changes.
Annual meeting set for November 13, 2026
Proxy statement and proxy to be distributed on or about September 28, 2026
Record date for the meeting was September 15, 2026
Exozymes sold 71,110 shares and 35,555 warrants to one investor on June 30, 2026, for gross proceeds of $639,990 before about $74,799 in commissions and other expenses. The company says net proceeds will fund its NCT business and products, next-in-line products, research and development, and general corporate purposes. The warrants include a reset to $0.001 if the company sells shares below $8.99 before June 5, 2027, which could dilute existing holders.
Gross proceeds of $639,990, with commissions of $44,799 and other expenses of approximately $30,000
Each $18.00 unit included one share valued at $8.99 and one warrant valued at $0.02
Warrants are exercisable at $11.24 from June 5, 2027, to June 5, 2031, and reset to $0.001 on certain lower-priced sales before June 5, 2027
MDB Capital, the placement agent, received a warrant to buy 10,666 shares at $11.24
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every EXOZYMES INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →